Features | Partner Sites | Information | LinkXpress
Sign In
Agfa Healthcare
Schiller
ElsMed

Molecular Imaging Tracers Help Determine Brain Metastases Treatment Strategies

By Medimaging International staff writers
Posted on 17 Dec 2013
Imaging with the molecular imaging tracer 18F-FDOPA (L-3,4-dihydroxy-6-[18F]fluoro-phenylalanine) can help differentiate radiation-induced lesions from new tumor growth in patients who have been treated with radiotherapy for brain metastases, according to new research.

Using this amino acid tracer, researchers discovered that physicians could effectively differentiate the two types of lesions 83% of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging findings.

Brain metastases occur in 20%–40% of all cancer patients, especially in those with melanoma, non-small-cell lung cancer, and breast cancer. They account for 170,000 new cases yearly in the United States alone, and prognosis is poor. Treatment for brain metastases usually includes a combination of surgery, radiation treatment, and chemotherapy.

“Histopathological changes in neural tissue treated with radiation could trigger clinical and imaging manifestations which are very similar to those caused by tumor growth,” said Karlo J. Lizarraga, MD, MS, from the department of neurology, Miller School of Medicine, University of Miami (FL, USA), and lead author of the study. “The challenge is then to differentiate whether these manifestations are due to radiation or to tumor progression or recurrence. Accurate and timely distinction between these two possibilities can significantly affect patient care, and outcome for treatment modalities are completely different for each case.”

In the retrospective study, published ahead of print October 28, 2013, and slated for the January 1, 2014, issue of the Journal of Nuclear Medicine, researchers analyzed images from 32 patients who had 83 earlier irradiated brain metastases and who underwent 18F-FDOPA positron emission tomography (PET). The studies were analyzed both semi-quantitatively and visually to determine whether lesions were caused by radiation injury or were recurrent or progressive brain metastases. Results were verified by histopathologic analysis or clinical follow-up. The prognostic ability of 18F-FDOPA in predicting progression-free survival and overall survival was also studied with the Kaplan-Meier and Cox regression techniques.

The best overall accuracy for differentiating between the two types of lesions was achieved using visual scoring, which had a sensitivity of 81.3%, a specificity of 84.3%, and an overall accuracy of 83.1%. The semi-quantitative analysis resulted in a sensitivity of 81.3%, a specificity of 72.5% and an overall accuracy of 75.9%.

Researchers also discovered that evaluations with 18F-FDOPA PET was highly prognostic of progression-free survival, as lesions with a negative PET result had a mean time to progression that was 4.6 times longer than lesions with positive 18F-FDOPA PET findings. Moreover, a trend toward predicting overall survival was also seen.

18F-FDOPA PET imaging is currently available in few centers. The longer physical half-life of 18F-FDOPA, when compared to other amino acid tracers, gives it the advantage of potential automated production and transport to PET centers for widespread use,” noted Dr. Lizarraga.

Related Links:

Miller School of Medicine, University of Miami



Channels

Radiography

view channel
Image: Agfa HealthCare’s DX-D Mobile Retrofit solution will allow hospitals an easy and affordable way to upgrade existing GE Healthcare’s AMX 4 and 4 plus mobile X-ray systems to direct radiography (DR) (Photo courtesy of Agfa Healthcare).

Retrofit Enables Cost-Effective Upgrade of Existing Mobile X-Ray Systems to Direct Radiography

A mobile retrofit system has been designed to be mounted on mobile X-ray systems to create an easy way for hospitals to go digital without having to replace existing mobile X-ray units. A direct radiography... Read more

MRI

view channel
Image: The ischemic penumbra is visible in some patients up to 24 hour after stroke by MRI scanning. Perfusion-weighted imaging can be used to show areas of ischemia and can be compared with the ischemic core, visible by diffusion-weighted imaging (Photo courtesy of sharinginginhealth dot ca, an open access training in healthcare resource).

Diffusion-Weighted MRI Becoming Major Tool to Diagnose Patients with Transient Ischemic Attacks

With the development of brain imaging, including cranial computed tomography (CCT), and particularly diffusion-weighted imaging-magnetic resonance imaging (DWI-MRI), the diagnosis of transient ischemic... Read more

Ultrasound

view channel
Image: Ultrasound image of the Circle of Willis (Photo courtesy of the Swedish Cerebrovascular Center, Seattle, WA, USA).

New Approaches for Transcanial Ultrasound Used for the Treatment of Brain Tumors and Targeted Drug Delivery

A study completed by a Finnish researcher provides new insights into the limitations and potential new directions for the future advancement of transcranial ultrasound therapy. Active research is ongoing... Read more

General/Advanced Imaging

view channel

Diagnostic Imaging Tests Ordered by General Practitioners in Australia Nearly Double in 10 Years

A 45% increase in diagnostic imaging tests ordered by Australian general practitioners (GPs) is being fueled by increasing GP visits, an escalating number of problems managed at doctor visits, and a higher probability that GPs order imaging tests for these problems, according to a new study. Based on a long-term national... Read more

Imaging IT

view channel
Image: An X-ray using the ClearRead bone suppression software technology (Photo courtesy of Riverain Technologies).

Bone Suppression Software Used to Optimize Diagnostic Capability of X-Ray Systems

Clinicians are gathering important information from the most routine imaging exam, the chest X-ray, by using advanced software that enhances X-ray images captured by the equipment they already have or... Read more

Industry News

view channel

Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.